Literature DB >> 22457520

Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses.

Jens C Krause1, Tshidi Tsibane, Terrence M Tumpey, Chelsey J Huffman, Randy Albrecht, David L Blum, Irene Ramos, Ana Fernandez-Sesma, Kathryn M Edwards, Adolfo García-Sastre, Christopher F Basler, James E Crowe.   

Abstract

Investigation of the human antibody response to the 1957 pandemic H2N2 influenza A virus has been largely limited to serologic studies. We generated five influenza virus hemagglutinin (HA)-reactive human monoclonal antibodies (MAbs) by hybridoma technology from the peripheral blood of healthy donors who were born between 1950 and 1968. Two MAbs reacted with the pandemic H2N2 virus, two recognized the pandemic H3N2 virus, and remarkably, one reacted with both the pandemic H2N2 and H3N2 viruses. Each of these five naturally occurring MAbs displayed hemagglutination inhibition activity, suggesting specificity for the globular head domain of influenza virus HA. When incubated with virus, MAbs 8F8, 8M2, and 2G1 each elicited H2N2 escape mutations immediately adjacent to the receptor-binding domain on the HA globular head in embryonated chicken eggs. All H2N2-specific MAbs were able to inhibit a 2006 swine H2N3 influenza virus. MAbs 8M2 and 2G1 shared the V(H)1-69 germ line gene, but these antibodies were otherwise not genetically related. Each antibody was able to protect mice in a lethal H2N2 virus challenge. Thus, even 43 years after circulation of H2N2 viruses, these subjects possessed peripheral blood B cells encoding potent inhibiting antibodies specific for a conserved region on the globular head of the pandemic H2 HA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457520      PMCID: PMC3372199          DOI: 10.1128/JVI.07158-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

Authors:  David I Bernstein; Kathryn M Edwards; Cornelia L Dekker; Robert Belshe; Helen K B Talbot; Irene L Graham; Diana L Noah; Fenhua He; Heather Hill
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

2.  Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5.

Authors:  Nobuko Ohshima; Yoshitaka Iba; Ritsuko Kubota-Koketsu; Yoshizo Asano; Yoshinobu Okuno; Yoshikazu Kurosawa
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

3.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

4.  An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Authors:  Xiaocong Yu; Patricia A McGraw; Frances S House; James E Crowe
Journal:  J Immunol Methods       Date:  2008-05-05       Impact factor: 2.303

5.  Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

Authors:  Xiaocong Yu; Tshidi Tsibane; Patricia A McGraw; Frances S House; Christopher J Keefer; Mark D Hicar; Terrence M Tumpey; Claudia Pappas; Lucy A Perrone; Osvaldo Martinez; James Stevens; Ian A Wilson; Patricia V Aguilar; Eric L Altschuler; Christopher F Basler; James E Crowe
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

6.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

7.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.

Authors:  Jianhua Sui; William C Hwang; Sandra Perez; Ge Wei; Daniel Aird; Li-mei Chen; Eugenio Santelli; Boguslaw Stec; Greg Cadwell; Maryam Ali; Hongquan Wan; Akikazu Murakami; Anuradha Yammanuru; Thomas Han; Nancy J Cox; Laurie A Bankston; Ruben O Donis; Robert C Liddington; Wayne A Marasco
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

8.  Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.

Authors:  Reiko Yoshida; Manabu Igarashi; Hiroichi Ozaki; Noriko Kishida; Daisuke Tomabechi; Hiroshi Kida; Kimihito Ito; Ayato Takada
Journal:  PLoS Pathog       Date:  2009-03-20       Impact factor: 6.823

9.  BioHealthBase: informatics support in the elucidation of influenza virus host pathogen interactions and virulence.

Authors:  Burke Squires; Catherine Macken; Adolfo Garcia-Sastre; Shubhada Godbole; Jyothi Noronha; Victoria Hunt; Roger Chang; Christopher N Larsen; Ed Klem; Kevin Biersack; Richard H Scheuermann
Journal:  Nucleic Acids Res       Date:  2007-10-26       Impact factor: 16.971

10.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis.

Authors:  Xavier Brochet; Marie-Paule Lefranc; Véronique Giudicelli
Journal:  Nucleic Acids Res       Date:  2008-05-24       Impact factor: 16.971

View more
  42 in total

1.  Recombinant influenza A H3N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics.

Authors:  Jianqiang Zhou; Shun Xu; Jun Ma; Wen Lei; Kang Liu; Qiliang Liu; Yida Ren; Chunyi Xue; Yongchang Cao
Journal:  Virus Genes       Date:  2013-11-23       Impact factor: 2.332

2.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 4.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

Review 5.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

6.  Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Authors:  Florian Krammer; Natalie Pica; Rong Hai; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

7.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

8.  Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Authors:  Florian Krammer; Peter Palese
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 9.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

Review 10.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.